AIDS Healthcare Foundation (AHF) denounces Gilead Sciences for once again excluding Latin America and the Caribbean (LAC) from affordable access to a groundbreaking HIV prevention drug, lenacapavir.

India's Glenmark Pharmaceuticals said on Thursday its innovation arm, Ichnos Glenmark Innovation (IGI), and AbbVie have ...

AbbVie partners with IGI Therapeutics for ISB 2001, a potential cancer and autoimmune therapy. Read more here.

AbbVie has struck an immuno-oncology licensing agreement with IGI Therapeutics that is potentially worth more than $1.9 billion to the clinical-stage biotechnology company.

The U.S. House of Representatives committee on China on Tuesday sent a letter to the directors of the FBI and national ...

The drugmaker will provide, at no profit, doses to treat up to 2 million people in resource-limited countries. Meanwhile, Arvinas' John Houston is retiring from his role leading the biotech.

Through a strategic, non-profit agreement, Gilead will supply up to two million doses of the long-acting HIV prevention drug ...